Regeneron Pharmaceuticals, Inc.
COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER

Abstract:

The present disclosure provides methods for treating or inhibiting the growth of cancer comprising selecting a patient with cancer and administering a therapeutically effective amount of a LAG-3 inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, the administration of the PD-1 inhibitor enhances the efficacy of a LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in inhibiting the growth of cancer.